TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16888468

Group type: EXPERIMENTAL
Intervention: Physical education classes (first or second semester)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (some or meeting Healthy People 2010 guidelines)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 214

Group type: COMPARATOR
Intervention: Physical education class enrollment or physical activity levels
Number of subjects: 214
Study: 12796154

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micro g)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micro g)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 10860897

Group type: EXPERIMENTAL
Intervention: zidovudine/didanosine/nevirapine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine/delavirdine
Number of subjects: 74
Study: 8864639

Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg/day, once daily)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 2000
Study: 1332433

Group type: EXPERIMENTAL
Intervention: Interactional therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 89
Study: 3006981

Group type: EXPERIMENTAL
Intervention: 40, 80, or 160 mg propranolol (non‐selective blockade)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25, 50, or 100 mg atenolol (beta 1‐selective blockade)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31883330

Group type: EXPERIMENTAL
Intervention: CTCA-guided management
Number of subjects: 4146

Group type: COMPARATOR
Intervention: Standard care plus CTCA
Number of subjects: 4146
Study: 29289579

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions (exercise on a Swiss ball, lumbosacral massage, warm shower)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual maternity unit care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 80
Study: 26094600

Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Index (AFI)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Single Deepest Vertical Pocket (SDP)
Number of subjects: 1052
Study: 24438582

Group type: EXPERIMENTAL
Intervention: Community-based interventions focusing on changing beliefs and cognitions related to sexual practices (Mankweng, Limpopo, South Africa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention promoting improved parent-offspring communication on sexuality (Kampala, Uganda)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention promoting healthy sexual practices (Western Cape, South Africa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-based peer education intervention (Dar es Salaam, Tanzania)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention arms (control group)
Number of subjects: 0
Study: 22387995

Group type: EXPERIMENTAL
Intervention: Motivational and self-efficacy variables
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Previous quit attempts
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 849
Study: 20143382

Group type: EXPERIMENTAL
Intervention: Multifaith spiritually based intervention (SBI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both SBI and CBT
Number of subjects: 22
Study: 18391642

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 200
Study: 19516160

Group type: EXPERIMENTAL
Intervention: Community-based exercise intervention
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Randomized women
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Participant demographics
Number of subjects: 3200
Study: 16167233

Group type: EXPERIMENTAL
Intervention: Dietary fiber
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no dietary fiber)
Number of subjects: 56
Study: 11252115

Group type: EXPERIMENTAL
Intervention: Papanicolaou-stained smears of bronchoalveolar lavage fluid
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (normal subjects and patients with other pulmonary disorders)
Number of subjects: 7
Study: 9135343

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1 (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol 4 mg kg‐1 (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol 5 mg kg‐1 (group C)
Number of subjects: 0
Study: 7971302

Group type: EXPERIMENTAL
Intervention: Distraction technique using a kaleidoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard preparation (control)
Number of subjects: 100
Study: 3545579

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 68
Study: 11978335

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 9014
Study: 29664001

Group type: EXPERIMENTAL
Intervention: Mild hypothermia started at 2 hours after onset
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mild hypothermia started at 4 hours after onset
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mild hypothermia started at 6 hours after onset
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mild hypothermia treatment
Number of subjects: 93
Study: 27484576

Group type: EXPERIMENTAL
Intervention: Intravenous glutamate
Number of subjects: 824

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 824
Study: 24233244

Group type: EXPERIMENTAL
Intervention: Moderate intensity training (T(vent); 55-65 % VO(2max))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low intensity training (Fat-Max; 30-40% VO(2max))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 25
Study: 22268137

Group type: EXPERIMENTAL
Intervention: Automated control of pressure support ventilation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standardized written protocol (control group)
Number of subjects: 300
Study: 20386120

Group type: EXPERIMENTAL
Intervention: beta-alanine (BA, n = 14) 1.5 g + 15 g dextrose powder
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: placebo (PL, n = 19) 16.5 g dextrose powder
Number of subjects: 44

Group type: COMPARATOR
Intervention: control (CON, n = 11)
Number of subjects: 44
Study: 18559698

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 154
Study: 15955378

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine)
Number of subjects: 56
Study: 12461343

Group type: EXPERIMENTAL
Intervention: Hylan B gel
Number of subjects: 83

Group type: COMPARATOR
Intervention: Bovine collagen
Number of subjects: 83
Study: 10608577

Group type: EXPERIMENTAL
Intervention: Treatment with sex steroids
Number of subjects: 49
Study: 7791589

Group type: EXPERIMENTAL
Intervention: Simulated hyperoxia (FIO2 62.2%)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Simulated hypoxia (FIO2 15.8%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normoxia (FIO2 20.9%)
Number of subjects: 6
Study: 1646341

Group type: EXPERIMENTAL
Intervention: 30 mg AG-1749 (lansoprazole)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60 mg AG-1749 (lansoprazole)
Number of subjects: 8

Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 8
Study: 7032303

Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment five times daily for 14 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: 3% vidarabine ointment five times daily for 14 days
Number of subjects: 41
Study: 30807853

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (oral vitamin B12 tablets) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Number of subjects: 188
Study: 29902295

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Erlotinib (150 mg/d)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d) with ERBB mutation-positive disease
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d) without ERBB mutation-positive disease
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: HER2 mutations in afatinib-treated patients
Number of subjects: 245
Study: 27081739

Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose tacrolimus (EVR + rTAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose tacrolimus (TAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose tacrolimus (EVR + rTAC) in hepatitis-C sub-population
Number of subjects: 0
Study: 24840756

Group type: EXPERIMENTAL
Intervention: Caffeine therapy
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 1433
Study: 22578752

Group type: EXPERIMENTAL
Intervention: Early oxytocin augmentation
Number of subjects: 536

Group type: COMPARATOR
Intervention: Postponed oxytocin augmentation
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Operative births
Number of subjects: 536

Group type: COMPARATOR
Intervention: Both early and postponed oxytocin treatment groups
Number of subjects: 536
Study: 21031585

Group type: EXPERIMENTAL
Intervention: Caffeine (n = 33)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 70
Study: 18931201

Group type: EXPERIMENTAL
Intervention: Aprotinin (approximately 5-6 x 10(6) Kallikrein Inhibiting Units)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Tranexamic acid (approximately 6 g)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Aprotinin (CABG patients)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Aprotinin and Tranexamic acid
Number of subjects: 220
Study: 16094794

Group type: EXPERIMENTAL
Intervention: Creative arts intervention
Number of subjects: 0
Study: 12756096

Group type: COMPARATOR
Intervention: Control strip biopsy specimen used in phase 3 for difficult slides
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Original diagnoses by 5 pathologists in phase 1 and 3
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intraobserver evaluations by 5 pathologists in phase 2
Number of subjects: 27
Study: 10951891

Group type: EXPERIMENTAL
Intervention: nedocromil sodium 2% ophthalmic solution b.i.d.
Number of subjects: 189
Study: 9592262

Group type: EXPERIMENTAL
Intervention: Tinidazole (TNZ)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Metronidazole (MNZ)
Number of subjects: 52
Study: 1557575

Group type: EXPERIMENTAL
Intervention: Experimental regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 0
Study: 3901862

Group type: EXPERIMENTAL
Intervention: Long acting local anaesthetic injected into the pseudoarthrosis immediately after skin closure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injected into the other side
Number of subjects: 20
Study: 30797391

Group type: EXPERIMENTAL
Intervention: Enhanced Telephone Monitoring (ETM)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 298
Study: 29954814

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 376

Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (SOC)
Number of subjects: 376
Study: 27254033

Group type: COMPARATOR
Intervention: Bivalent oral poliovirus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine
Number of subjects: 0
Study: 25242048

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg daily) plus prednisone (5 mg twice a day)
Number of subjects: 2314
Study: 23134881

Group type: EXPERIMENTAL
Intervention: 5 portions/d of fruit and vegetables for 16 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: 2 portions/d of fruit and vegetables
Number of subjects: 83
Study: 20974558

Group type: EXPERIMENTAL
Intervention: Belotero® Basic
Number of subjects: 20

Group type: COMPARATOR
Intervention: Restylane®
Number of subjects: 20
Study: 17687266

Group type: EXPERIMENTAL
Intervention: Lithium treatment in bipolar patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Unmedicated bipolar patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 33
Study: 15843762

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (Li+)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (DVPX)
Number of subjects: 60
Study: 12429243

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.25% ophthalmic solution, one drop 4 times daily in the affected eye.
Number of subjects: 459

Group type: COMPARATOR
Intervention: Neomycin-polymyxin-B-gramicidin ophthalmic solution, one drop 4 times daily in the affected eye.
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.25% ophthalmic solution
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.25% ophthalmic solution and Neomycin-polymyxin-B-gramicidin
Number of subjects: 459
Study: 9428493

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Polychemotherapy (cisplatin and cyclophosphamide)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cisplatin (for patients with tumors not expressing bcl-2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Other biomarkers (p53, bcl-2, GST-pi)
Number of subjects: 168
Study: 7926328

Group type: EXPERIMENTAL
Intervention: Feedback of the tonic stretch reflex training
Number of subjects: 8

Group type: COMPARATOR
Intervention: No reflex training (Control)
Number of subjects: 8
Study: 2803883

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 49
Study: 788722

Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 33
Study: 29495020

Group type: EXPERIMENTAL
Intervention: Resin-based sealants (with and without fluoride)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Nontreatment (control group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Sealants (total retention rate)
Number of subjects: 400
Study: 27854422

Group type: EXPERIMENTAL
Intervention: Booster Break program
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual-break control group
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Individual-based computer-prompt intervention
Number of subjects: 175
Study: 24710470

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 102
Study: 22492518

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg, twice daily
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg, twice daily
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin (target INR 2-3)
Number of subjects: 18113
Study: 20424424

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (50 microg/kg/day, n = 45)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No treatment (n = 43)
Number of subjects: 88
Study: 18586683

Group type: EXPERIMENTAL
Intervention: Argatroban (1.0, 2.0, or 3.0 microg/kg/hr) + phenprocoumon or acenocoumarol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin K-antagonist alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing by immunologic and chromogenic assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Argatroban treatment
Number of subjects: 0
Study: 16103383

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) and sufentanil (5 microg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Thoracic epidural infusion of bupivacaine (0.25%) and fentanyl (2 microg/mL)
Number of subjects: 55
Study: 11839141

Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole (TMP‐SMZ)
Number of subjects: 842
Study: 10443606

Group type: EXPERIMENTAL
Intervention: 125 mg/kg epsilon‐ACA followed by an infusion of 12.5 mg x kg(‐1) x h(‐1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Equivalent volume of saline (control)
Number of subjects: 74
Study: 7821198

Group type: EXPERIMENTAL
Intervention: Segmental allergen provocation with 250 PNU in 5 ml 0.9% NaCl solution of birch or grass pollen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Segmental allergen provocation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control segment (saline instillation)
Number of subjects: 10
Study: 1974942

Group type: EXPERIMENTAL
Intervention: Feeding at one breast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Feeding at two breasts
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both feeding patterns
Number of subjects: 12
Study: 111322

Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 215

Group type: COMPARATOR
Intervention: VM‐26
Number of subjects: 215

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 215
Study: 6761088

Group type: EXPERIMENTAL
Intervention: 200 mg clotrimazole vaginal tablets
Number of subjects: 111

Group type: COMPARATOR
Intervention: 150 mg econazole vaginal ovules
Number of subjects: 111
Study: 30006020

Group type: EXPERIMENTAL
Intervention: Second-generation electronic cigarettes (ECIGs) with 0 or 18 ng/ml nicotine, used ad libitum for two weeks.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo electronic cigarettes (ECIGs), used ad libitum for two weeks.
Number of subjects: 25
Study: 30257752

Group type: EXPERIMENTAL
Intervention: Nurse-led pre-exposure prophylaxis (PrEP) model
Number of subjects: 8000
Study: 26749533

Group type: EXPERIMENTAL
Intervention: E-cigarettes (high, low, and zero nicotine products)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: E-cigarettes (for smokers with elevated BP)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: E-cigarettes (for continuous smoking phenotype)
Number of subjects: 145
Study: 24816809

Group type: EXPERIMENTAL
Intervention: Prasugrel plus bivalirudin
Number of subjects: 548

Group type: COMPARATOR
Intervention: Clopidogrel plus heparin
Number of subjects: 548
Study: 22070672

Group type: EXPERIMENTAL
Intervention: Analogy instruction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Explicit instruction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition (habitual pitch variation)
Number of subjects: 40
Study: 20518225

Group type: EXPERIMENTAL
Intervention: Weekly massage treatments at work for a four week period
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 28
Study: 17505694

Group type: EXPERIMENTAL
Intervention: Physical training associated with BiPAP (physical training+B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 18
Study: 14988337

Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (epinephrine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Volume resuscitation with normal saline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 21
Study: 12557618

Group type: EXPERIMENTAL
Intervention: Co-induction group (midazolam 3 mg, alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Number of subjects: 80
Study: 9829442

Group type: EXPERIMENTAL
Intervention: Percutaneous 17beta-estradiol gel (1.5 mg/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Transdermal 17beta-estradiol patch (50 microg/d)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral estradiol valerate (2 mg/d)
Number of subjects: 54
Study: 7911863

Group type: EXPERIMENTAL
Intervention: Metoprolol preadsorbed onto activated charcoal (100 mg metoprolol tartrate/120 mg charcoal)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pindolol preadsorbed onto activated charcoal (10 mg pindolol/20 mg charcoal)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Metoprolol control (capsule containing the drug only)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pindolol control (conventional tablet)
Number of subjects: 2
Study: 2686934

Group type: EXPERIMENTAL
Intervention: Atropine plus succinylcholine (2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atropine alone (20 micrograms/kg)
Number of subjects: 20
Study: 785952

Group type: EXPERIMENTAL
Intervention: Piracetam (1-acetamide-2-pyrrolidone)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31392517

Group type: EXPERIMENTAL
Intervention: Chloroquine 500 mg daily for 2-6 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27998241

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Group (WBVG)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Multicomponent Training Group (MTG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 38
Study: 26227099

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150 μg (therapeutic dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 240 μg (supratherapeutic dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23343062

Group type: EXPERIMENTAL
Intervention: Peginesatide (0.025 mg or 0.04 mg per kg, once a month)
Number of subjects: 983

Group type: COMPARATOR
Intervention: Darbepoetin (0.75 μg per kg, once every 2 weeks)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Peginesatide
Number of subjects: 983
Study: 22403966

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg before surgery, then twice a day for 2 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70
Study: 19777100

Group type: EXPERIMENTAL
Intervention: Small-group training
Number of subjects: 236

Group type: COMPARATOR
Intervention: Self-directed Internet-based training
Number of subjects: 236
Study: 17976288

Group type: EXPERIMENTAL
Intervention: Graduate mental health worker case management
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 62